Physician profile
Gregory Gibson
NPI 1467489120
$4,120.80
in general payments reported to CMS, 2019-2025
26 companies · $1,118 in 2025
The $1,118 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $611 · 2020: $208 · 2021: $356 · 2022: $329 · 2023: $701 · 2024: $797 · 2025: $1,118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,617.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,616.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,357.58 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $463.82 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Braintree Laboratories, INC. | $324.21 | 2019-2023 | Sutab |
| Janssen Biotech, INC. | $267.56 | 2019-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $262.80 | 2019-2025 | Entyvio, Eohilia |
| Qol Medical, LLC | $219.20 | 2023-2024 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $161.47 | 2024-2025 | Dupixent |
| Genzyme Corporation | $149.11 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $141.20 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $99.20 | 2024-2025 | Omvoh |
| Madrigal Pharmaceuticals | $94.13 | 2025 | Rezdiffra |
| Intercept Pharmaceuticals, INC. | $91.67 | 2019-2020 | |
| Pfizer INC. | $83.97 | 2023-2024 | |
| Redhill Biopharma INC. | $56.79 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $49.20 | 2023-2024 | Dificid |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $48.34 | 2020-2022 | |
| Merit Medical Systems INC | $38.72 | 2025 | Esophyx, Endomaxx Stent and Delivery System |
| Ferring Pharmaceuticals INC. | $34.43 | 2019 | |
| Boston Scientific Corporation | $30.40 | 2025 | Spyglass |
| Vivus LLC | $28.65 | 2025 | Pancreaze |
| Organon LLC | $24.00 | 2024 | |
| Aimmune Therapeutics, INC. | $21.43 | 2025 | Zenpep |
| Daiichi Sankyo INC. | $21.23 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $18.18 | 2023 | Bylvay |
| Ironwood Pharmaceuticals, INC | $18.05 | 2024 | |
| Shire North American Group INC | $15.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Gibson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.